Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

Nicole DeFeudis

Editor

Jason Coloma remembers when Maze Therapeutics was nothing more than a bunch of PowerPoint slides. Several months after revealing exactly what his team of scientists …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Some FDA medical device staff reinstated just days after receiving pink slips

How AI can address ongoing challenges in the life sciences industry

Maze Ther­a­peu­tics re­fu­els with an­oth­er $190M to prove its ge­net­ic mod­i­fiers ap­proach holds up in the clin­ic

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic